Buscar

Estamos realizando la búsqueda. Por favor, espere...

 Detalle_Publicacion

Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group

Abstract: This Policy Review presents the International Myeloma Working Group's clinical practice recommendations for the treatment of relapsed and refractory multiple myeloma. Based on the results of phase 2 and phase 3 trials, these recommendations are proposed for the treatment of patients with relapsed and refractory disease who have received one previous line of therapy, and for patients with relapsed and refractory multiple myeloma who have received two or more previous lines of therapy. These recommendations integrate the issue of drug access in both low-income and middle-income countries and in high-income countries to help guide real-world practice and thus improve patient outcomes.

 Fuente: Lancet Oncol . 2021 Mar;22(3):e105-e118

Editorial: Lancet Pub. Group

 Año de publicación: 2021

Nº de páginas: 14

Tipo de publicación: Artículo de Revista

 DOI: 10.1016/S1470-2045(20)30756-7

ISSN: 1470-2045,1474-5488

Url de la publicación: https://www.doi.org/10.1016/S1470-2045(20)30756-7

Autores/as

MOREAU, PHILIPPE

KUMAR, SHAJI K

SAN MIGUEL, JESÚS

DAVIES, FAITH

ZAMAGNI, ELENA

BAHLIS, NIZAR

LUDWIG, HEINZ

MIKHAEL, JOSEPH

TERPOS, EVANGELOS

SCHJESVOLD, FREDRIK

MARTIN, THOMAS

YONG, KWEE

DURIE, BRIAN G M

FACON, THIERRY

JURCZYSZYN, ARTUR

SIDANA, SURBHI

RAJE, NOOPUR

DONK, NIELS VAN DE